Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination

Abstract

Despite the mild immunosuppressive effects of daclizumab in vivo demonstrated by an increased incidence of infectious complications in clinical trials, patients with MS under daclizumab therapy mount normal antibody responses to influenza vaccinations.